La vendita allo scoperto per CASI Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CASI Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Report sulle vendite allo scoperto

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

CASINO GHRD PRC S/ADR by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>What could be better than viable enterprises within the biotechnology industry? Try <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> under $10.</p>



<p>Primarily, the reason why the sector is so popular among investors is its potential for addressing various diseases and conditions. Obviously, there&rsquo;s the human component of lengthening life and its quality. However, economic considerations exist as well. According to one study published by the National Institutes of Health&rsquo;s website, the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830426/#:~:text=Chronic%20diseases%20such%20as%20heart,COVID%2D19%20morbidity%20and%20mortality.&amp;text=The%20cost%20of%20chronic%20disease,reach%20%2447%20trillion%20by%202030.">total cost of chronic disease</a> worldwide may reach $47 trillion by 2030.</p>



<p>Second, biotech stocks benefit from a massive and burgeoning addressable market. Grand View Research states that the sector <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion last year</a>. Between 2024 to 2030, the segment could expand at a compound annual growth rate of 13.96%. At the culmination point, the ecosystem could be worth $3.88 trillion.</p>



<p>Add in the lower cost and potentially higher ceiling of biotech stocks under $10 and you have an extremely enticing opportunity. Below are a few ideas to consider.</p>



<h2>CASI Pharmaceuticals (CASI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in Beijing, China, <strong>CASI Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/casi-stock-quote/"><strong>CASI</strong></a>) develops and commercializes therapeutics and pharmaceutical products. Primarily, <a href="https://finance.yahoo.com/quote/CASI/profile/">the company brings to the table Evomela</a>, an intravenous formulation used as a conditioning treatment before stem cell transplantation. It also serves as a palliative treatment for patients with multiple myeloma.</p>



<p>To be upfront, CASI stock is all over the map. Since the start of the year, shares lost about 9% of equity value. However, in the past 52 weeks, they&rsquo;re up over 167%. In other words, speculators should gird themselves for a high-risk, high-reward opportunity. Financially, it doesn&rsquo;t get a whole lot better, with the company incurring a loss per share of 57 cents in the past four quarters.</p>



<p>The kicker is that analysts were anticipating a loss of 34 cents. Therefore, the average &ldquo;earnings&rdquo; surprise came out to 355% below parity. Further, experts believe that fiscal 2024 will be rough, leading to an erosion of almost 42% in the top line to $19.79 million.</p>



<p>However, they also see sales recovering in fiscal 2025 to $46.48 million, up nearly 135%. So, that&rsquo;s something to consider if you&rsquo;re looking into biotech stocks under $10.</p>



<h2>Kamada (KMDA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Located in Israel, <strong>Kamada</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/"><strong>KMDA</strong></a>) falls under the drug manufacturing ecosystem. Primarily, Kamada manufactures and sells plasma-derived protein therapeutics. Among its commercial products are Kamrab/Kedrab for treating <a href="https://finance.yahoo.com/quote/KMDA/profile/">prophylaxis of rabies</a>. It also offers Hepagam B for the prevention of hepatitis B recurrence among liver transplant patients.</p>



<p>Financially, Kamada is a much more attractive proposition. In the past year since the first quarter, the pharmaceutical firm posted an average earnings per share of 6 cents. This figure beat the collective consensus view of 4 cents, yielding an earnings surprise of 61.68%. Over the past 52 weeks, KMDA stock gained 20%. However, the price action has been choppy, so it&rsquo;s something to consider before taking a position.</p>



<p>Priced at 2.27X trailing-year sales, Kamada is undervalued. The underlying drug manufacturing space features a <a href="https://fullratio.com/ps-ratio-by-industry">price-to-sales ratio of 2.85X</a>.</p>



<p>Even better, analysts are projecting fiscal 2024 sales to land at $159.6 million, up 12% from the prior year. Fiscal 2025 revenue may bump up to $176.23 million, making the valuation more attractive. Thus, KMDA ranks among the top biotech stocks under $10.</p>



<h2>Valneva (VALN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>A specialty vaccine company, <strong>Valneva</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/valn-stock-quote/"><strong>VALN</strong></a>) develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet needs. Primarily, the company offers Ixiaro, a Vero cell culture-derived Japanese encephalitis vaccine. It also offers Dukoral, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera.</p>



<p>To be quite blunt, VALN may be the riskiest idea among biotech stocks under $10. Since the start of the year, shares lost more than 29% of equity value. Financially, the company posted an average loss per share of 10 cents in the past year since Q1. The problem is that covering experts anticipated an EPS of 24 cents during the period.</p>



<p>If we&rsquo;re being honest, VALN stock trades at a high sales multiple of 3.05X. In the past year, this metric was slightly more palatable at 2.41X. That said, patience could be a virtue.</p>



<p>For fiscal 2024, analysts believe that sales could rise to $187.21 million. If so, that would imply growth of 12.7% from the prior year. Also, fiscal 2025 revenue could hit $244.92 million, up 30.8%. That makes VALN one of the tempting biotech stocks under $10.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/07/3-promising-biotech-stocks-you-can-pick-up-for-less-than-10/">3 Promising Biotech Stocks You Can Pick Up for Less Than $10</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Promising Biotech Stocks You Can Pick Up for Less Than $10

CASI Pharmaceuticals GAAP EPS of -$0.52, revenue of $3.98M

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals reports a transition in company strategy towards developing treatments for...

CASI Pharmaceuticals Shifts Focus, Garners Investment

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>CASI Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/casi-stock-quote/"><strong>CASI</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>CASI Pharmaceuticals reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -63 cents.</li><li>The company reported revenue of $3.98 million.</li><li>This was 10.18% worse than the analyst estimate for revenue of $4.43 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/casi-stock-earnings-casi-pharmaceuticals-for-q2-of-2024/">CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024

Casi Pharmaceuticals files to sell 3M ordinary shares for holders.

Novartis expands U.S. radiopharma production amid rising competition

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals has restructured its senior management to better align with its strategic ...

CASI Pharmaceuticals Revamps Management Structure

CASI Pharmaceuticals (CASI) announced that the Center for Drug Evaluation of China's National Medical Products Administration has approved the Comp...

Casi Pharmaceuticals receives CTA approval from China NMPA for CID-103

CASI Pharmaceuticals Q3 Earnings Preview

Here's the major earnings before the open tomorrow

AFMD

ATNM

AZUL

BILI

BLUE

BTAI

CASI

CATX

CLRB

CRIS

CVSI

DTEGY

EONGY

ITRM

KEYUF

KMDA

KNTNF

LNTH

LUNR

MKGAF

NICE

NLCP

NTES

NVSEF

OCUL

ONEW

PAVM

PDSB

POLA

PVCT

QBTS

SACH

SIEGY

SPCB

VALN

VEON

VISL

WKHS

XNET

Earnings

Press Releases

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Small Cap

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Ligand Reports Second Quarter 2024 Financial Results

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Comments

CASI Pharmaceuticals

Vendite allo scoperto

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO